Xiaocheng Chen, Ph.D., serves as the head of antibody engineering at Vivace Therapeutics. Prior to joining Vivace, she was a scientist and lab lead in the Antibody & Protein Engineering department at Denali Therapeutics, where she led an antibody engineering group and contributed to projects ranging from the establishment of antibody display platform to antibody discovery, engineering and characterization. Dr. Chen completed her B.S. in biochemistry at Nanjing University in China and her doctoral degree in structural biology at the University of Texas Southwestern Medical Center. She continued her postdoctoral training in biophysics and structural biology at the Howard Hughes Medical Institute before joining Genentech. During her tenure in the department of Antibody Engineering at Genentech, she collaborated with discovery and pre-clinical teams and identified/engineered therapeutic antibodies for IND filing. The disease areas Dr. Chen has been working on include oncology, immunology, infectious diseases and neurodegenerative diseases. Dr. Chen has authored 10 peer-reviewed journal articles and is an inventor on five published patents.